Effective Date: 08/23/18 Date Reviewed/ Date Revised: 08/23/18

ACTIVATED PARTIAL THROMBOPLASTIN TIME

Sta Compact Max

I. PRINCIPLE

The activated partial thromboplastin time (APTT) is a general coagulation screening test of the coagulation factors XII, XI, IX, and VIII, X, V, II and fibrinogen.

II. CLINICAL SIGNIFICANCE

A prolongation of the APTT is encountered in the following situations:

- A. Congenital Deficiencies
 - 1. If the prothrombin time (PT) is normal, the following factors may be deficient: factor VII, IX, XI, XII.
 - 2. If all these factors are normal, a deficiency in the following should be considered: prekallikrein (Fletcher factor) or HMW kiningen (Fitzgerald factor).
- B. Acquired Deficiencies and Abnormal Conditions
 - Liver diseases
 - 2. Consumptive coagulopathy
 - 3. Fibrinolysis
 - 4. Circulating anticoagulants (LA type or circulating anticoagulant against a factor)
 - 5. During heparin or oral anticoagulant therapy
 - 6. Treatments with thrombin inhibitors (e.g., hirudin, argatroban).

III. SPECIMEN

- A. 2.7 ml or 1.8 ml Blue Top Tube. Mix nine parts of freshly collected blood with one part of 0.11 mol/L (3.2%) sodium citrate anticoagulant. Invert the tube gently three or four times immediately after venipuncture to ensure proper mixing of blood an anticoagulant.
 - If blood is drawn from an indwelling catheter, the line should be flushed with 5.0 mL saline and the first 5 mL of blood or six dead space volumes of the catheter discarded.
- B. The citrate concentration must be adjusted in patients who have hematocrit values above 55%. See STA Compact Max Start Up Operating Procedure.
- C. Specimens that are clotted, collected in the wrong tube, have visible hemolysis or have less than a 90% fill or >10% overfill are rejected.
- D. It is unacceptable to combine the contents from separate under-filled sodium citrate tubes.

E. Handling/ Storage Conditions:

- The whole blood specimen is checked for clot formation by gently inversion and observation.
- 2. Centrifuge the capped blood specimen as soon as possible after collection for 2 minutes at 7200 RPM (3500 x g) in the Stat Spin Express 3 or S/P[®] Brand Stat-60.
 - a. Testing requires produce platelet-poor plasma (platelet count <10x10⁹/L).
 - The plasma may remain on the packed cells if testing immediately or separated if freezing.

Effective Date: 08/23/18 Date Reviewed/ Date Revised: 08/23/18

- c. To separate plasma, use a plastic transfer pipette; remove the plasma to a polypropylene/ plastic tube until ready to test.
- 3. If testing is not complete within acceptable time for specimen stability (see below), the plasma must be removed to a polypropylene/ plastic tube and frozen. A frost-free freezer should not be used. Frozen plasma samples must be rapidly thawed at 37°C while gently mixing and tested immediately after thawing.
- 4. If testing is delayed, the sample may be held for 4 hours at room temperature.
- Specimens should be stored on board the analyzer or at room temperature after testing. Once removed from the analyzer, caps must be removed if additional testing is ordered.

IV. REAGENTS

- A. STA® PTT A 5 reagent containing cephalin prepared from rabbit cerebral tissues and a particulate activator (silica) in a buffered medium, lyophilized.
 - Preparation: Reconstitute each vial with 5 ml of fresh reagent grade Nerl water. Allow
 the reconstituted material to stand at room temperature (18-25 °C) for 30 minutes.
 Mix vigorously by turning the vial upside down 5-10 times or vortex to obtain a
 homogeneous solution and install the perforated plastic cap on the vial.
 - 2. Storage: The reagent in intact vials is stable until the expiration date indicated on the box label, when stored at 2-8 °C.

Once reconstituted, the reagent is stable:

- 24 hours on STA Compact[®] with the perforated cap in place
- 7 days at 2-8 °C in its original capped vial.

Do not freeze the reagent.

- B. STA® CaCl₂ 0.025 M 0.025 M CaCl₂ solution.
 - 1. Solution Preparation: If the solution is refrigerated, allow it to stand at room temperature (18-25 °C) for 30 minutes, before use.
 - Solution Storage: The solution in intact bottles is stable until the expiration date indicated on the box label, when stored at 2-25 °C.

After opening, it remains stable for:

- 3 days on and STA Compact[®]
- C. STA® Coag Control N + ABN Plus kit: provides a normal plasma and an abnormal plasma intended for the quality control of the following tests on analyzers of the STA® brand name suitable with these reagents: prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen.
 - 1. Preparation: Reconstitute each vial of Reagent 1 or 2 with exactly 2 ml of fresh reagent grade Nerl water. Allow the reconstituted material to stand at room temperature (18-25 °C) for 30 minutes. Then, swirl the vial gently before use.
 - 2. Storage: The reagents in intact vials are stable until the expiration date indicated on the box label, when stored at 2-8 °C. Once reconstituted, Reagents 1 and 2 remain stable for 24 hours.
- D. STA DESORB U is a decontaminating solution for use with the STA Compact[®] It is designed as an integral part of the STA analyzer system.

Effective Date: 08/23/18 Date Reviewed/ Date Revised: 08/23/18

- 1. Preparation: Install a new STA® maxi Reducer) and the perforated cap on a freshly opened bottle of STA® Desorb U before loading it into the analyzer.
 - N.B.: a fine white sediment may be observed in the bottom of the bottle; this has no effect on the performance of the product.
 - On STA Compact® model, place one bottle in the product drawer.
- 2. Storage: The reagent in intact bottles is stable until the expiration date indicated on the box label, when stored at 2-8 °C and protected from light.

Once opened, the STA® - Desorb U with STA® - maxi Reducer and perforated cap in place, is stable for 5 days on board STA Compact®

The STA® - Desorb U reagent contains KOH, a corrosive chemical at the concentration provided (< 1 %).

Danger:

- Causes severe skin burns and eye damage.
- b. Wear protective gloves/protective clothing/eye protection/face protection.
- c. IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with water/shower.
- d. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

V. INSTRUMENTATION/EQUIPMENT

- A. STA Compact®
- B. Cuvette roll 1000 (REF 38669)
- C. NERL or Distilled Water
- D. Pipettes & tips

VI. CALIBRATION

No calibration of the system in necessary for performing an APTT if the results are reported in seconds.

VII. QUALITY CONTROL

- A. It is necessary to run controls in order to ensure accuracy and reproducibility of the results. Two different levels of control should be used.
- B. <u>Daily QC Schedule for the N and Abn Plus controls</u>: Check product status→After morning run, perform daily maintenance.
 - Quality control for PT and APTT is automatically run when the STA Compact Max[®]
 has to perform an analysis using that methodology and when the time since the last
 control exceeds 8 hours. The time period is defined in the METHODOLOGIES
 screens
 - 2. 09:00-09:30 Make up new QC and any reagents needed
 - 3. <u>09:30-10:00</u> Load QC material and Manually run QC
 - Reconstituted Coag Control Plus N+ABN is stable onboard the Sta Compact Max for 24 hours
 - 4. 17:30-18:00 Manually run QC if sample are not being run
 - 5. <u>01:30-02:00</u> Manually run QC if sample are not being run
 - 6. QC will automatically run when testing switches to a new vial of reagent.

Effective Date: 08/23/18 Date Reviewed/ Date Revised: 08/23/18

- C. If Quality Control is not within acceptable range, check that all the components of the test system are functioning correctly, i.e., reagents, assay conditions, etc. If necessary, repeat the tests
- D. See STA Compact Max Start Up Operating Procedure or Reference Manual for further information

VIII. PROCEDURE:

- A. Refer to STA Compact Max Start Up Operating Procedure for the analyzer before running patient and QC specimens at the start of each shift.
- B. There are two modes to load samples.
 - Automatic Mode:
 - a. Instrument is connected to a LIS and can download testing
 - b. Load sample onto instrument and the tests will auto-populate with test ordered in LIS
 - 2. Manual Mode used for LIS downtime or Interface downtime:
 - a. Instrument is either not linked to a LIS, or sample is not ordered in the LIS
 - b. Load sample onto instrument, then select the test(s) to be performed

IX. REPORTING RESULTS

Report results using interface/manual result entry in the LIS system. Reference interval for UPH-Pekin for APTT's: 23.7 - 34.7 seconds.

- A. Procedure for Abnormal Results:
 - 1. Critical Value: APTT's ≥ 127 seconds
 - 2. Analytical Measurement Range: 10 220 seconds
 - a. Below AMR turn out as <10 seconds
 - b. Above AMR turn out as >220 seconds

LIMITATIONS OF THE PROCEDURE X.

- A. When monitoring heparin therapy, any release of platelet factor 4 (PF4) which is a potent inhibitor of heparin, represents a major source of error. Do not collect blood in glass, which might cause this release; collect blood in plastic, siliconized glass or CTAD tubes.
- B. Perform centrifugation within 1 hour after sample collection if the blood was collected in conventional citrate anticoagulant.

XI. REFERENCES

- A. STA Compact Max[®] Reference Manual June 2016.
 B. STA Compact Max[®] User Guide November 2015.
- C. STA Compact Max[®] Software version 106.08.01.00

Effective Date: 08/23/18 Date Reviewed/ Date Revised: 08/23/18

| POLICY CREATION: | Date |
|---|----------|
| Author: Kelly Hall, MT (ASCP) | 08/23/18 |
| Medical Director: Kathryn O. Kramer, M.D. | 08/23/18 |

| MEDICAL DIRECTOR | | | | | |
|--------------------------|-----------------------|-----------|--|--|--|
| DATE | NAME | SIGNATURE | | | |
| 8-24-18 | Kathryh O. Kramer | To o | | | |
| SECTION MEDICAL DIRECTOR | | | | | |
| | $\Lambda//_{\Lambda}$ | | | | |
| | 11// | | | | |
| | | | | | |

| Lead | Date | Coordinator/ Manager | Date | Medical Director | Date |
|------|------|-------------------------|------|------------------|------|
| | | | | | |
| | | | | | |

| REVISION HISTORY (began tracking 2011) | | | | | |
|--|-----------------------|--------|----------------|--|--|
| Rev | Description of Change | Author | Effective Date | | |
| | | | | | |
| | | | | | |
| | | | | | |